Condition | Psychiatric

ASPIRE

  • IRB Number: 1112B
  • Contact Name: Terrance Bellnier, RPh, MPA, FASCP
  • Status: Enrolling
  • Phone: 585-739-5880
  • Lead Researcher: Kashinath Patil, MD

Description

For patients with schizophrenia. All participants receive active medication in the double-blind study (247). Once randomized, they are eligible to participate in an open label study (248) of the Abilify long-acting depot for up to two years or when the medication is approved by the FDA.